This company listing is no longer active
8IN Stock Overview
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Syneos Health, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$40.00 |
52 Week High | US$51.08 |
52 Week Low | US$25.67 |
Beta | 1.58 |
1 Month Change | 3.63% |
3 Month Change | 3.63% |
1 Year Change | -17.96% |
3 Year Change | -14.53% |
5 Year Change | -7.26% |
Change since IPO | 37.91% |
Recent News & Updates
Recent updates
Shareholder Returns
8IN | DE Life Sciences | DE Market | |
---|---|---|---|
7D | 1.5% | -0.4% | 1.1% |
1Y | -18.0% | -3.9% | 16.0% |
Return vs Industry: 8IN exceeded the German Life Sciences industry which returned -22.5% over the past year.
Return vs Market: 8IN underperformed the German Market which returned 5.9% over the past year.
Price Volatility
8IN volatility | |
---|---|
8IN Average Weekly Movement | 1.8% |
Life Sciences Industry Average Movement | 7.0% |
Market Average Movement | 6.6% |
10% most volatile stocks in DE Market | 12.8% |
10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 8IN has not had significant price volatility in the past 3 months.
Volatility Over Time: 8IN's weekly volatility has decreased from 8% to 2% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 28,768 | Michelle Keefe | www.syneoshealth.com |
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development.
Syneos Health, Inc. Fundamentals Summary
8IN fundamental statistics | |
---|---|
Market cap | €4.22b |
Earnings (TTM) | €67.43m |
Revenue (TTM) | €5.13b |
Is 8IN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
8IN income statement (TTM) | |
---|---|
Revenue | US$5.42b |
Cost of Revenue | US$4.22b |
Gross Profit | US$1.20b |
Other Expenses | US$1.13b |
Earnings | US$71.22m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.69 |
Gross Margin | 22.14% |
Net Profit Margin | 1.31% |
Debt/Equity Ratio | 75.8% |
How did 8IN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2023/09/28 01:51 |
End of Day Share Price | 2023/09/27 00:00 |
Earnings | 2023/06/30 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syneos Health, Inc. is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Gregory Bolan | Avondale Partners |
Eric Coldwell | Baird |
Stewart Glickman | CFRA Equity Research |